Patient portrayal of a woman enjoying time with family Patient portrayal of a woman enjoying time with family

In eligible adults with newly
diagnosed FLT3-ITD+ AML,
VANFLYTA is the
only FDA-approved
treatment made to
specifically target
your type of AML

VANFLYTA is a targeted therapy

VANFLYTA is designed to target the ITD mutation. VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation. It is not known if VANFLYTA is safe and effective in children. VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant.

Representation of FLT3-ITD+ AML cancer cells quickly growing and dividing

FLT3-ITD+ AML cancer cells
grow and divide quickly

Representation of FLT3-ITD+ AML cancer cells quickly growing and dividing

VANFLYTA targets FLT3-ITD+ AML
cancer cells and helps stop them
from growing or dividing

Representation of VANFLYTA targeting FLT3-ITD+ AML cancer cells and helping to stop them from growing

Fewer cancer cells may mean healthy red and white blood cells can start to develop again

VANFLYTA patient portrayal
VANFLYTA specifically
works on the FLT3-ITD
mutation, and may help
slow down or stop
cancer cells from
dividing and growing
Not an actual patient.
VANFLYTA patient portrayal
VANFLYTA specifically works on the FLT3-ITD mutation, and may help slow down or stop cancer cells from dividing and growing
Not an actual patient.